Detailed analysis from the randomized, double-blind, placebo-controlled Phase 3 TRIUMpH-NERD study demonstrated that both ...
From implementation to adoptionAs of October 2026, the use of generative AI in companies has reached a clear turning point.
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, ...
RB Global, Inc. (NYSE: RBA) (TSX: RBA) ("RB Global" or the "Company") today announced executive leadership appointments and organizational updates to position the Company for its next phase of growth ...
The FDA-aligned pivotal efficacy population includes 12 male patients receiving commercial-grade RP-A501 at the recalibrated dose. The first three patients treated under the modified protocol count ...
Vaults are where onchain capital is heading. Curated vault assets have grown 39% over the past year and users have deposited more than $10 billion into Morpho in the last two years, around $1 billion ...
Rovensa Next, the global leader in biosolutions for agriculture, has today announced at Fruit Attraction the evolution of its global Biosolutionize Agriculture campaign, marking the next phase of the ...
The CCYO stated that it is therefore compelled to take this decisive step in defence of the rights, dignity, customs and ...
Pharmazz Inc. announced that U.S. Food and Drug Administration (FDA) has cleared the Company?s Investigational New Drug (IND) application to proceed with a pivotal Phase 3 clinical trial evaluating ...
(Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 ...
One of Roivant’s leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning. The program, known as IMVT-1402 or imeroprubart, did ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results